We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current VIRP market cap is 3.03B. The company's latest EPS is EUR 14.3412 and P/E is 24.96.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 948.93M | 1.03B | 1.08B | 1.23B | 1.26B |
| Operating Income | 107.38M | 202.21M | 187.56M | 207.72M | 213.66M |
| Net Income | 51.55M | 136.04M | 113.16M | 121.97M | 121.3M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 1.32B | 1.11B | 1.2B | 1.33B | 1.46B |
| Total Liabilities | 771.38M | 454.28M | 476.36M | 494.53M | 545.81M |
| Total Equity | 551.88M | 655.22M | 725.19M | 838.98M | 909.92M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | 131.61M | 118.92M | 129.9M | 98.99M | 118.64M |
| Investing | -16.13M | 339.52M | -51.22M | -54.83M | -121.87M |
| Financing | -79.48M | -349.89M | -91.69M | -34.76M | -2.72M |
| Market Cap | 3.03B |
| Price to Earnings Ratio | 24.96 |
| Price to Sales Ratio | 2.39 |
| Price to Cash Ratio | 17.21 |
| Price to Book Ratio | 3.33 |
| Dividend Yield | 0.37% |
| Shares Outstanding | 8.46M |
| Average Volume (1 week) | 2.11k |
| Average Volume (1 Month) | 4.35k |
| 52 Week Change | 20.95% |
| 52 Week High | 377.50 |
| 52 Week Low | 232.50 |
| Spread (Intraday) | 17.5 (4.82%) |
| Company Name | Virbac SA |
| Address |
1ere avenue 2065 m lid carros 06516 |
| Website | https://www.virbac.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
